Enhanced antitumor effect of docetaxel by combined exposure of thalidomide in human prostate cancer cells
- At: 2013 FIP Congress in Dublin (Ireland)
- Type: Poster
- By: TAMAKI, Hiroki (Shimane University Hospital, Pharmacy, Izumo-shi, Japan)
- Co-author(s): Nishimura, Nobuhiro (Shimane University Hospital, Izumo-shi, Japan)
Naora, Kohji (Shimane University Hospital, Izumo-shi, Japan)
Background and Aims:
Thalidomide (THA) has been approved for the treatment of multiple myeloma in Japan. Recently, it has been reported that the combination therapy of THA with docetaxel (DTX) prolonged overall survival time in patients with castration resistant prostate cancer. The aim of this research is to clarify the mechanism of enhanced.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.